Lab Power | Predictions for 2025
A forecast of the year by Bill Kerr, M.D., MBA, CEO of Avalon Healthcare Solutions.
As 2025 approaches, the healthcare landscape is undergoing rapid transformation. Rising healthcare utilization, escalating costs and surging demand for specialized drugs like GLP-1 [glucagon-like peptide 1] therapies are intensifying the need for innovative solutions. One critical strategy lies in harnessing the power of lab data.
Kerr
By leveraging comprehensive lab insights, payers and employers can identify patients eligible for targeted treatments, stratify them by risk and ensure that costly medications are prescribed judiciously. This data-driven approach not only helps manage expenses but also improves patient outcomes.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Evaluating the Cost-Effectiveness of NSCLC Treatments: New Insights From a Recent Review
January 17th 2025But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.
Read More
